Dacomitinib and Proferrin-ES

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

By reducing the acidity level in the stomach, raNITIdine may interfere with the absorption of dacomitinib and reduce its effectiveness. You should generally take dacomitinib at least 6 hours before or 10 hours after raNITIdine. Talk to your doctor or pharmacist if you have questions on how to take these or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

ADJUST DOSING INTERVAL: Coadministration with proton pump inhibitors (PPIs) may decrease the plasma concentrations of dacomitinib. The proposed mechanism is a pH-dependent reduction in dissolution or absorption of dacomitinib due to prolonged gastric acid suppression induced by PPIs. When a single 45 mg dose of dacomitinib was coadministered with rabeprazole (40 mg once daily for 7 days) in 24 healthy subjects, dacomitinib peak plasma concentration (Cmax) and systemic exposure (AUC 0 to 96 hours) decreased by approximately 51% and 39%, respectively, compared to dacomitinib administered alone. By contrast, administration of dacomitinib with a local antacid (aluminum hydroxide-magnesium hydroxide 400 mg-400 mg/5 mL) did not cause clinically relevant changes in dacomitinib concentrations. The lack of a significant interaction may be due to the shorter duration of action of antacids relative to PPIs. The interaction has not been studied with H2-receptor antagonists. Based on pooled data in clinical study patients, H2-receptor antagonists had no apparent effect on steady-state trough concentration of dacomitinib.

MANAGEMENT: The manufacturer recommends taking dacomitinib at least 6 hours before or 10 hours after H2-receptor antagonists. As an alternative, locally-acting antacids may be considered. Concomitant use of dacomitinib with PPIs should generally be avoided.

Dacomitinib

Generic Name: dacomitinib

Brand name: Vizimpro

Synonyms: n.a.

What is Dacomitinib?

Proferrin-ES

Generic Name: heme iron polypeptide

Brand name: Proferrin-ES, Baciguent, Probiotic Formula

Synonyms: n.a.

What is Proferrin-ES?